4/11/2012

AnaptysBio and Celgene agreed to jointly develop antibodies against oncology and inflammation-related targets using the former's SHM-XEL platform. Celgene will get worldwide development and commercialization rights to antibodies discovered by its partner. AnaptysBio will receive an upfront fee, plus milestone payments and sales royalties.

Related Summaries